Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics symbols : Otlk save search
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
Published: 2024-04-22 (Crawled : 22:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
macular growth market
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -0.93%
H: 5.85%
C: 2.46%
therapeutics million
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 52.98%
H: 8.82%
C: -19.87%
ons-5010 therapeutics chmp positive treatment
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -2.5%
H: 1.71%
C: -2.44%
therapeutics million
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 1793.07%
H: 3.89%
C: -5.51%
therapeutics
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 4.47%
H: 5.29%
C: 0.57%
therapeutics first year update financial results
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: -9.77%
therapeutics first
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
Published: 2024-01-23 (Crawled : 13:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 20.59%
H: 11.24%
C: 8.24%
ons-5010 therapeutics day fda million agreement
ROSEN, LEADING TRIAL ATTORNEYS, Encourages NuScale Power Corporation Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SMR
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -0.25%
H: 8.21%
C: 6.35%
EH | $17.315 1.85% 1.82% 840K
|
Technology Services
|
| O: -1.27%
H: 0.45%
C: -0.45%
corporation deadline trial
OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
Published: 2024-01-02 (Crawled : 20:00) - prnewswire.com
SLRN | $4.6 -4.56% -4.78% 2M
|
|
| O: 1.51%
H: 1.12%
C: -5.09%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -0.25%
H: 8.21%
C: 6.35%
EH | $17.315 1.85% 1.82% 840K
|
Technology Services
|
| O: -1.27%
H: 0.45%
C: -0.45%
deadline
RBLX Investors Have Opportunity to Lead Roblox Corporation Securities Fraud Lawsuit
Published: 2024-01-02 (Crawled : 17:00) - prnewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 2.39%
H: 6.12%
C: -2.55%
corporation
ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SLRN | $4.6 -4.56% -4.78% 2M
|
|
| O: 0.2%
H: 0.0%
C: -2.36%
SEDG 4 | $56.71 4.04% 2.94% 2.7M
|
Producer Manufacturing
|
| O: -0.23%
H: 0.66%
C: -3.02%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 5.16%
H: 3.25%
C: -12.19%
deadline
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
Published: 2023-12-28 (Crawled : 18:00) - prnewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 5.16%
H: 3.25%
C: -12.19%
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
Published: 2023-12-28 (Crawled : 14:00) - prnewswire.com
FMC A | $58.65 0.69% 0.0% 1.6M
|
Process Industries
|
| O: 0.08%
H: 0.0%
C: -0.58%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: -9.02%
EGRX | $4.78 5.06% 4.81% 88K
|
Health Technology
|
| O: 0.96%
H: 4.58%
C: 3.34%
deadline
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN
Published: 2023-12-26 (Crawled : 19:00) - prnewswire.com
LICY | $0.7121 -1.68% 0.1% 1.6M
|
|
| O: 1.22%
H: 4.4%
C: 0.73%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 12.11%
H: 0.0%
C: -7.48%
ILMN | $124.41 3.46% 3.34% 1.3M
|
Health Technology
|
| O: 0.62%
H: 0.88%
C: 0.72%
deadline trial
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
Published: 2023-12-26 (Crawled : 18:00) - prnewswire.com
LICY | $0.7121 -1.68% 0.1% 1.6M
|
|
| O: 3.4%
H: 7.89%
C: 2.05%
SCYX | $1.53 6.25% 5.88% 150K
|
Health Technology
|
| O: 1.08%
H: 3.27%
C: 1.6%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 1.63%
H: 4.65%
C: 3.72%
deadline
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
Published: 2023-12-22 (Crawled : 13:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 2.71%
H: 3.3%
C: -3.73%
ons-5010 therapeutics year financial results
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
Published: 2023-12-20 (Crawled : 16:00) - prnewswire.com
SCYX | $1.53 6.25% 5.88% 150K
|
Health Technology
|
| O: 0.0%
H: 0.26%
C: -2.63%
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -3.29%
H: 16.47%
C: 4.67%
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: -1.48%
H: 4.0%
C: -2.95%
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
Published: 2023-12-19 (Crawled : 13:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -1.86%
H: 12.16%
C: 11.81%
ons-5010 therapeutics fda study
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Published: 2023-12-17 (Crawled : 20:20) - prnewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 0.65%
H: 5.52%
C: -2.38%
AHCO | $9.79 1.98% 1.94% 970K
|
Finance
|
| O: 1.16%
H: 3.07%
C: -1.53%
deadline global
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.